Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and PEG-Interferon-alpha in Advanced Cutaneous Squamous Cell Carcinoma
NCT05729139Phase 1Withdrawn
- Sponsor
- Baptist Health South Florida
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cemiplimab and interferon alfa in cutaneous squamous cell carcinoma (cSCC), sponsored by Baptist Health South Florida. Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs) at 2 years. Planned start Jul 2023; status: withdrawn.
02
Drugs
cemiplimabinterferon alfa
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05729139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05729139.